Influencing factors on the NMP-22 urine assay: an experimental model.
Influencing factors on the NMP-22 urine assay: an experimental model.
复制标题
DOI：
10.1186/1471-2490-12-23
复制
发表时间：
2012-08-28
期刊：
影响因子：
2
通讯作者：
Rosser CJ
中科院分区：
文献类型：
--
作者：
Miyake M;Goodison S;Giacoia EG;Rizwani W;Ross S;Rosser CJ
用于膀胱癌（BCa）的市售NMP-22尿液检测试剂盒使用单克隆抗体检测核有丝分裂器蛋白1（NUMA 1）。目前尚不清楚这些检测是否在监测肿瘤抗原或与疾病状态相关的其他现象。在本研究中，我们研究了尿细胞和蛋白浓度以及血尿对实验模型中NMP-22检测性能的影响。在用NMP 22 ®膀胱癌ELISA测试和NMP 22 ® BladderChek®床旁测试进行分析之前，将来自健康受试者的合并尿液掺入不同浓度的良性（UROtsa）细胞、癌细胞（RT 4、T24、KU-7和UM-UC-14）、全血或血清。对照受试者的尿液对NMP-22呈阴性。添加50 ul/10 ml全血而非血清导致假阳性结果。此外，添加高浓度的良性尿路上皮细胞（106）或来自这些细胞的细胞裂解物（306 μg蛋白质）导致假阳性结果。高浓度的合并癌细胞（106）或细胞裂解物（30.6 μg及以上）导致NMP-22试验呈阳性。NMP-22 ELISA测定和NMP-22护理点测定之间的一致性> 90%。尿NMP-22测定不是检测特异性肿瘤抗原，而是测量可能通过各种条件（包括膀胱肿瘤的表面脱落）引入尿液的细胞构成或细胞更新量。在某些情况下，由于病变特征或采样时间而缺乏显著的尿细胞结构可能导致假阴性NMP-2检测。
The commercial NMP-22 urine assays for bladder cancer (BCa) detect nuclear mitotic apparatus protein 1 (NUMA1) using monoclonal antibodies. It remains unclear whether these assays are monitoring a tumor antigen or some other phenomenon associated with the disease state. In this study, we investigated the influence of urinary cellular and protein concentration, and hematuria on the performance of the NMP-22 tests in an experimental model. Pooled urine from healthy subjects were spiked with varying concentrations of benign (UROtsa) cells, cancer cells (RT4, T24, KU-7 and UM-UC-14), whole blood or serum, prior to analysis with both NMP22® Bladder Cancer ELISA test and the NMP22® BladderChek® point-of-care test. Urines from control subjects were negative for NMP-22. The addition of whole blood at 50ul/10 ml, but not serum, resulted in a false-positive result. Furthermore, the addition of a high concentration of benign urothelial cells (106) or the cell lysate from these cells (306 μg protein) resulted in a false-positive result. High concentrations of pooled-cancer cells (106) or cell lysate (30.6 μg and above) resulted in a positive NMP-22 assay. Concordance between the NMP-22 ELISA assay and the NMP-22 point of care assay was >90%. Rather than detecting a specific tumor antigen, urinary NMP-22 assays may be measuring the cellularity or amount of cell turnover that may be introduced into the urine by a variety of conditions, including surface shedding from bladder tumors. The absence of significant urinary cellularity in some cases due to lesion characteristics or the timing of sampling may result in false-negative NMP-2 assays.
登录
查看更多内容
影响因子：
120.7
作者：
Grossman, HB;Messing, E;Shen, Y
通讯作者：
Shen, Y
影响因子：
23.4
作者：
Sözen, S;Biri, H;Bozkirli, I
通讯作者：
Bozkirli, I
影响因子：
4.5
作者：
Huber, Severine;Schwentner, Christian;Stenzl, Arnulf
通讯作者：
Stenzl, Arnulf
影响因子：
7
作者：
Uhlén, M;Björling, E;Pontén, F
通讯作者：
Pontén, F
影响因子：
6.6
作者：
Boman, H;Hedelin, H;Holmäng, S
通讯作者：
Holmäng, S